Immunoglobulin G1 [234-Alanine,235-Glutamic Acid,237-Alanine,330-Serine,331-Serine], Anti-(Human C5A Anaphylatoxin Chemotactic Receptor 1) (Human Monoclonal Tj210001 ?1-Chain), Disulfide With Human Monoclonal Tj210001 ?-Chain, Dimer
Neoplasm
Explore 889 assets in Neoplasm →Floatz Rating
C39/100
Confidence
Indicative
Sponsor
I-Mab Biopharma US Limited
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04678921CT.gov Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1 [234-Alanine,235-Glutamic Acid,237-Alanine,330-Serine,331-Serine], Anti-(Human C5A Anaphylatoxin Chemotactic Receptor 1) (Human Monoclonal Tj210001 ?1-Chain), Disulfide With Human Monoclonal Tj210001 ?-Chain, Dimer (this asset) | I-Mab Biopharma US Limited | P1 | C · 39 |
| Panitumumab | Astellas Pharma Inc | P2 | BB |
| Irinotecan | Mirati Therapeutics Inc. | P4 | BB |
| Nivestim | Ankara Etlik City Hospital | P2 | BB |
| Dexasone | Hellenic Society of Hematology | P3 | BB |
| Feladilimab | GlaxoSmithKline | P2 | BB |
| Carboplatin | Bristol-Myers Squibb | P3 | BB |
| Pralsetinib, Trans- | Seoul National University Bundang Hospital | P3 | BB |
| Granulocyte Colony-Stimulating Factor Lenograstim | Sanofi | P4 | BB |
+42 more in the Neoplasm cohort
Other indications for Immunoglobulin G1 [234-Alanine,235-Glutamic Acid,237-Alanine,330-Serine,331-Serine], Anti-(Human C5A Anaphylatoxin Chemotactic Receptor 1) (Human Monoclonal Tj210001 ?1-Chain), Disulfide With Human Monoclonal Tj210001 ?-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Malignant Neoplasm | — | P1 | CC · 42 |
| Cancer | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1 [234-Alanine,235-Glutamic Acid,237-Alanine,330-Serine,331-Serine], Anti-(Human C5A Anaphylatoxin Chemotactic Receptor 1) (Human Monoclonal Tj210001 ?1-Chain), Disulfide With Human Monoclonal Tj210001 ?-Chain, Dimer in Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-234-alanine235-glutamic-acid237-alanine330-serine331-serine-anti-human-c5a-anaphylatoxin-chemotactic-receptor-1-human-monoclonal-tj210001-1-chain-disulfide-with-human-monoclonal-tj210001-chain-dimer-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →